The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a twice-yearly therapy that allows administration during patients routine visits to their healthcare professionals and potentially contributes to improved patient adherence and sustained lower LDL-C levels. The Company is a subsidiary of Novartis AG.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq			5-day change	1st Jan Change
- ^USD	-.--%		+0.14%	-0.05%

20-01-06	The Medicines Company Announces Board Changes	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	CI

Market Cap	6.79B 5.85B 5.49B 5.01B 9.44B 649B 9.47B 65.09B 25.4B 328B 25.5B 24.94B 1,086B	P/E 2017	-2.79x	P/E 2018	-11.4x
Enterprise Value	7.34B 6.33B 5.93B 5.42B 10.2B 702B 10.23B 70.38B 27.46B 354B 27.57B 26.97B 1,175B	EV / Sales 2017	55.1x	EV / Sales 2018	319x
Free-Float	92.97%	Yield 2017 *	-	Yield 2018	-

20-01-06	The Medicines Company Announces Board Changes	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P TMI Index	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 1000	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Global BMI Index	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Composite 1500	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Biotechnology Select Industry Index	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from NASDAQ Biotechnology Index	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from NASDAQ Composite Index	CI
20-01-02	Novartis AG completed the acquisition of The Medicines Company.	CI
19-11-25	World share markets rally on revived trade hopes; dollar gains	RE
19-11-25	World share markets rally on revived trade hopes; dollar gains	RE

24-04-19	Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases	AQ
20-01-07	The Medicines Company : Announces Effective Date of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022	AQ
20-01-06	The Medicines Company : Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024	BU
20-01-06	MEDICINES CO /DE : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
20-01-06	MEDICINES CO /DE : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

The Medicines Company Stock

Stocks

MDCO

US5846881051

Pharmaceuticals

Valuation : The Medicines Company

Latest news : The Medicines Company

Press Releases : The Medicines Company

News in other languages : The Medicines Company

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

20-01-06	Medicines : Novartis bringt Übernahme von US-Biotech-Firma in trockene Tücher
19-12-30	Les fusions-acquisitions soutenues par la vigueur du marché américain en 2019
19-12-05	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
19-11-26	Des marchés dopés à l'optimisme
19-11-25	Point marchés-Les actions profitent des espoirs sur le commerce et des M&A

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/6/20	Geno Germano	Issuer sale	Director	52,223	0.0653%
1/6/20	Sarissa Capital Management LP	Issuer sale	Company	4,202,000	5.2569%
1/6/20	Peter Wijngaard	Issuer sale	Chief Development Officer	309,362	0.3870%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.35%	+0.93%	+20.41%	+72.72%	48.2B
OTSUKA HOLDINGS CO., LTD.	-0.08%	-0.21%	+56.71%	+119.95%	39.97B
ZYDUS LIFESCIENCES LIMITED	+0.15%	+6.34%	+21.40%	+88.46%	12.43B
CIPLA LIMITED	+0.25%	-0.61%	-10.44%	+15.76%	12.03B
KRKA, D. D.	+0.19%	0.00%	+29.35%	+151.21%	9.35B
GEDEON RICHTER	+0.07%	+3.80%	+30.19%	+45.41%	7.75B
GLENMARK PHARMACEUTICALS LIMITED	+2.24%	+8.50%	+30.72%	+232.43%	7.43B
ONO PHARMACEUTICAL CO., LTD.	+0.04%	+0.37%	+48.28%	-11.16%	7.22B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.53%	-1.53%	-36.09%	+15.18%	5.3B
Average	+0.27%	+2.10%	+21.17%	+81.11%	15.65B
Weighted average by Cap.	+0.22%	+1.36%	+28.63%	+87.39%

	2017	2018
Net sales	44.79M 38.59M 36.19M 33.03M 62.23M 4.28B 62.43M 429M 168M 2.16B 168M 165M 7.17B	6.14M 5.29M 4.96M 4.53M 8.53M 587M 8.56M 58.84M 22.96M 296M 23.05M 22.54M 982M
Net income	-708M -610M -572M -522M -984M -67.7B -987M -6.79B -2.65B -34.18B -2.66B -2.6B -113B	-123M -106M -99.5M -90.83M -171M -11.77B -172M -1.18B -461M -5.94B -462M -452M -19.7B
Net Debt	498M 429M 402M 367M 692M 47.58B 694M 4.77B 1.86B 24.02B 1.87B 1.83B 79.64B	552M 475M 446M 407M 767M 52.74B 769M 5.29B 2.06B 26.62B 2.07B 2.03B 88.28B